• Biogen and Eisai unveil details for five-year, real-world Aduhelm clinical trial

    1 month ago - By MedCity News

    Patients taking new Alzheimer's disease drug Aduhelm will be evaluated in a real-world study lasting up to five years. Biogen announced plans for the observational study, which is one of three post-marketing clinical programs planned to generate more data about the drug
    Read more ...